Since RT can directly affect or kill T cells, even at low doses, we aimed to define the tumor-specific CD8+ T cell response after either total-body or tumor-only LD RT preconditioning combined with DC vaccine therapy, compared with DC vaccine therapy alone, to try to understand further the potential mechanism by which LD RT improves tumor growth and mouse survival. The gene discussed is CD8A; the disease is neoplasm.